Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Non-Current Assets (2019 - 2025)

Harmony Biosciences Holdings' Non-Current Assets history spans 7 years, with the latest figure at $364.6 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 13.18% to $364.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $364.6 million, a 13.18% decrease, with the full-year FY2025 number at $364.6 million, down 13.18% from a year prior.
  • Non-Current Assets hit $364.6 million in Q4 2025 for Harmony Biosciences Holdings, down from $369.4 million in the prior quarter.
  • Over the last five years, Non-Current Assets for HRMY hit a ceiling of $419.9 million in Q4 2024 and a floor of $149.0 million in Q4 2021.
  • Historically, Non-Current Assets has averaged $297.4 million across 5 years, with a median of $309.7 million in 2023.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 115.38% in 2021 and later decreased 13.18% in 2025.
  • Tracing HRMY's Non-Current Assets over 5 years: stood at $149.0 million in 2021, then skyrocketed by 83.61% to $273.6 million in 2022, then surged by 31.72% to $360.4 million in 2023, then grew by 16.53% to $419.9 million in 2024, then decreased by 13.18% to $364.6 million in 2025.
  • Business Quant data shows Non-Current Assets for HRMY at $364.6 million in Q4 2025, $369.4 million in Q3 2025, and $416.7 million in Q2 2025.